Urticaria (Hives): Treatment Strategies and Management

Urticaria presents as transient, pruritic wheals. Acute (<6 weeks) often resolves spontaneously; chronic (>6 weeks) requires structured management.

Stepwise Treatment Algorithm

Step 1: Second-Generation H₁ Antihistamines (First-Line)

  • Cetirizine, loratadine, fexofenadine, desloratadine – non-sedating, once daily.
  • Updose to 2–4× standard dose if inadequate control (per EAACI/GA²LEN guidelines).

Step 2: Add-On Therapies

  • H₂ antagonist (famotidine 20–40 mg BID) – synergistic for some.
  • Leukotriene receptor antagonist (montelukast 10 mg HS) – especially if NSAID-exacerbated.
  • First-generation antihistamine (doxepin 10–25 mg HS) – potent H₁/H₂ blockade; sedating.

Step 3: Refractory Chronic Urticaria

  • Omalizumab (Xolair) 300 mg SC q4wks: Anti-IgE; FDA-approved for chronic spontaneous urticaria unresponsive to H₁. High response rate.
  • Cyclosporine: Calcineurin inhibitor; effective but requires renal/BP monitoring.
  • Short-course corticosteroids: Prednisone 0.5 mg/kg × 3–7 days for flares only—avoid chronic use.

Step 4: Emerging/Adjunctive

  • BTK inhibitors (remibrutinib), anti-IL-4/13 (dupilumab) – under investigation.
  • Phototherapy (NB-UVB) – limited evidence.

Lifestyle & Trigger Management

  • Keep a symptom diary (food, meds, stress, heat, pressure, menses).
  • Avoid confirmed triggers (NSAIDs, alcohol, tight clothing, overheating).
  • Cool compresses, fragrance-free moisturizers for symptomatic relief.

When to Refer

  • Angioedema without wheals (consider hereditary angioedema/C1-INH deficiency).
  • Systemic symptoms (fever, joint pain, bruising) – evaluate for vasculitis, autoimmunity.
  • Poor response to omalizumab + cyclosporine – specialist immunology/allergy review.

Most chronic urticaria remits within 1–5 years. Goal: symptom control with minimal medication burden.

Urinary Disorders - Related Articles